← Back to Clinical Trials
Recruiting NCT03581318

NCT03581318 Technical and Translational Development of Cardiovascular Magnetic Resonance (CMR) Imaging

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03581318
Status Recruiting
Phase —
Sponsor National Heart, Lung, and Blood Institute (NHLBI)
Condition Normal and Abnormal Cardiovascular Physiology
Study Type OBSERVATIONAL
Enrollment 5,000 participants
Start Date 2018-07-12
Primary Completion 2028-04-01

Eligibility & Interventions

Sex All sexes
Min Age 7 Years
Max Age 100 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 5,000 participants in total. It began in 2018-07-12 with a primary completion date of 2028-04-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Background: Magnetic resonance imaging (MRI) is an important non-invasive tool to study and diagnose cardiovascular disease. MRI scanners use strong magnetic fields and radio waves to create pictures of body organs. Researchers want to find better MRI methods and new ways of imaging cardiovascular disease and better understand normal and abnormal cardiovascular and brain function. Researchers are also interested in seeing if gadolinium, the commonly used MRI contrast agent, stays in the body long after the MRI was performed. Objectives: To develop new methods for imaging the heart and other organs of the body. To describe cardiovascular diseases using newer MRI methods To look at the relationship between cardiovascular disease and cardiovascular risk factors and other organ systems To look for gadolinium deposits in the brain from prior exams. Eligibility: Healthy people and people with known or suspected cardiovascular disease ages 7 and older may be eligible for this study. Researchers may be particularly interested in those who: * Have suspected or known cardiovascular disease * Were previously exposed to a gadolinium-based contrast agent, * Need to have a heart MRI scheduled * Need a test of the heart or other body part or will be undergoing a future cardiac catheterization Design: There are multiple arms to the study with optional components; therefore, there are multiple variations as to what an individual participant s experience may involve. Participants will have an MRI scan lasting up to 2 hours. The scanner is a large hollow tube. During the scan, there may be loud knocking and buzzing sounds caused by the scanner. Participants will lie on a table that slides in and out of the tube. Their vital signs may be monitored. Participants may have a test of heart electrical activity using wires connected to pads on the skin. Participants may have blood drawn. Participants may be injected with an MRI contrast agent through a plastic tube inserted in the arm.

Eligibility Criteria

* INCLUSION CRITERIA FOR HEALTHY VOLUNTEERS: * Age \>= 7 years * Able to follow instructions and lie still in the MRI scanner * Currently without known Cardiovascular disease * Able to provide informed consent in writing or provide guardian consent * Willingness to cooperate with all study procedures and available for scheduled study events EXCLUSION CRITERIA FOR HEALTHY VOLUNTEERS: * Important past or chronic medical illness such as major cardiovascular conditions like myocardial infarction, congenital heart disease, and known cardiomyopathy * Conditions that are thought to make MRI unsafe (that will be determined by filling out a separate form) including: * Cardiac pacemaker or implantable defibrillator unless it is labeled safe or conditional for MRI * Cerebral aneurysm clip unless it is labeled safe for MRI * Neural stimulator (e.g. TENS-Unit) unless it is labeled safe for MRI * Any type of ear or cochlear implant unless it is labeled safe for MRI * Ocular foreign body (e.g. metal shavings) * Metal shrapnel or bullet unless cleared by plain x-ray as safe for MRI * Any implanted device (e.g. insulin pump, drug infusion device), unless it is labeled safe or conditional for MRI * eGFR \< 60 mL/min/1.73m\^2 using the 2021 CKD-EPI equation or equivalent (using the CRIScalculated eGFR to define the threshold) and a serum creatinine measured within 2 weeks without intercurrent change in medical condition or medications. Subjects meeting this exclusion criterion may still be included in the study but may not be exposed to gadolinium-based contrast agents * Pregnancy. When uncertain of pregnancy status, subjects will undergo serum or urine pregnancy testing within the 7 days prior to the examination. Among those subjects who will receive MRI contrast, subjects of child-bearing potential will under serum or urine pregnancy testing within 7 days of the day prior to examination. In addition, the subject will be asked if she may be pregnant prior to the performance of the MRI, even if the pregnancy test was negative within the past week. The pregnancy test will be repeated if she answers in the affirmative. Post-menopausal and surgically sterilized subjects are automatically exempt from this testing. * If receiving contrast, breast feeding women (unless subject is willing to discard breast milk for 24 hours) are excluded * Healthy volunteer children will not have contrast * In a year's time, healthy volunteers are not restricted as to the number of non-contrast MRI examinations they undergo, but they may not undergo more than two examinations involving gadolinium-based contrast agents (GBCA) and those exposures will be at least 18 hours (12 half-lives) apart. INCLUSION CRITERIA FOR SUBJECTS WITH KNOWN OR SUSPECTED WITH HEART DISEASE: * Age \>= 7 years * Subjects with known or suspected cardiovascular disease * Able to provide informed consent in writing or provide guardian consent * Willingness to cooperate with all study procedures (including food restriction) and available for scheduled study events EXCLUSION CRITERIA FOR SUBJECTS WITH KNOWN OR SUSPECTED HEART DISEASE: * Conditions that are thought to make MRI unsafe (that will be determined by filling out a separate form) including: * Cardiac pacemaker or implantable defibrillator unless it is labeled safe or conditional for MRI * Cerebral aneurysm clip unless it is labeled safe for MRI * Neural stimulator (e.g. TENS-Unit) unless it is labeled safe for MRI * Any type of ear or cochlear implant unless it is labeled safe for MRI * Ocular foreign body (e.g. metal shavings) * Metal shrapnel or bullet unless cleared by plain x-ray as safe for MRI * Any implanted device (e.g. insulin pump, drug infusion device), unless it is labeled safe or conditional for MRI * Pregnancy. When uncertain of pregnancy status, subjects will undergo serum or urine pregnancy testing within the 7 days prior to the examination. Among those subjects who will receive MRI contrast, subjects of child-bearing potential will undergo serum or urine pregnancy testing 7 days prior to examination. In addition, the subject will be asked if she may be pregnant prior to the performance of the MRI, even if the pregnancy test was negative within the past week. The pregnancy test will be repeated if she answers in the affirmative. Post-menopausal and surgically sterilized subjects are automatically exempt from this testing. * Breast feeding (unless subject is willing to discard breast milk for 24 hours if receiving contrast) * eGFR \< 30 mL/min/1.73m\^2 using the 2021 CKD-EPI equation or Community Practice Standard for Pediatric case or equivalent and a serum creatinine measured within 2 weeks without intercurrent change in medical condition or medications. Subjects meeting this exclusion criterion may still be included in the study but may not be exposed to gadolinium-based contrast agents * Cardiorespiratory instability as determined by the enrolling clinician INCLUSION CRITERIA FOR SUBJECTS WITH NON-CARDIAC DISEASE: * Age \>= 7 years * Able to provide informed consent in writing or provide guardian consent * Willingness to cooperate with all study procedures (including food restriction) and available for scheduled study events * Known or suspected brain, hematology, oncology, endocrine, pulmonary, or other non-cardiac disease. EXCLUSION CRITERIA FOR SUBJECTS WITH NON- CARDIAC DISEASE: * Conditions that are thought to make MRI unsafe (that will be determined by filling out a separate screening form) including: * Cardiac pacemaker or implantable defibrillator unless it is labeled safe or conditional for MRI * Cerebral aneurysm clip unless it is labeled safe for MRI * Neural stimulator (e.g. TENS-Unit) unless it is labeled safe for MRI * Any type of ear or cochlear implant unless it is labeled safe for MRI * Ocular foreign body (e.g. metal shavings) * Metal shrapnel or bullet unless cleared by plain x-ray as safe for MRI * Any implanted device (e.g. insulin pump, drug infusion device), unless it is labeled safe or conditional for MRI * Pregnancy. When uncertain of pregnancy status, subjects will undergo serum or urine pregnancy testing within the 7 days prior to the examination. Among those subjects who will receive MRI contrast, subjects of child-bearing potential will undergo serum or urine pregnancy testing on the day of the examination. In addition, the subject will be asked if she may be pregnant prior to the performance of the MRI, even if the pregnancy test was negative within the past week. The pregnancy test will be repeated if she answers in the affirmative. Post-menopausal and surgically sterilized subjects are automatically exempt from this testing. * Breast feeding in those subjects receiving contrast (unless subject is willing to discard breast milk for 24 hours * eGFR \< 30 mL/min/1.73m\^2 using the 2021 CKD-EPI equation or equivalent and a serum creatinine measured within 2 weeks without intercurrent change in medical condition or medications. Subjects meeting this exclusion criterion may still be included in the study but may not be exposed to gadolinium-based contrast agents * Cardiorespiratory instability or as determined by the enrolling clinician

Contact & Investigator

Central Contact

Jennifer L Henry, R.N.

✉ henryjl@nhlbi.nih.gov

📞 (301) 827-6720

Principal Investigator

W. Patricia Bandettini, M.D.

PRINCIPAL INVESTIGATOR

National Heart, Lung, and Blood Institute (NHLBI)

Frequently Asked Questions

Who can join the NCT03581318 clinical trial?

This trial is open to participants of all sexes, aged 7 Years or older, up to 100 Years, studying Normal and Abnormal Cardiovascular Physiology. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03581318 currently recruiting?

Yes, NCT03581318 is actively recruiting participants. Contact the research team at henryjl@nhlbi.nih.gov for enrollment information.

Where is the NCT03581318 trial being conducted?

This trial is being conducted at Bethesda, United States.

Who is sponsoring the NCT03581318 clinical trial?

NCT03581318 is sponsored by National Heart, Lung, and Blood Institute (NHLBI). The principal investigator is W. Patricia Bandettini, M.D. at National Heart, Lung, and Blood Institute (NHLBI). The trial plans to enroll 5,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology